Skip to main content
SpringerLink
Log in

B-Type Natriuretic Peptide and Renal Disease

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

B-type natriuretic peptide (BNP) is a cardiac neurohormone which has a principal effect on the kidney to signal both natriuresis and diuresis. Both BNP and renal function are prognostic indicators of survival in patients with congestive heart failure (CHF). However, the relationships between BNP, renal function, and CHF as an emergency diagnosis, are not completely understood. The correlation between BNP and estimated glomerular filtration rate (eGFR) is approximately r = −0.20. At an eGFR <60 ml/min/1.73 m2, the optimum cutpoint for BNP to diagnose CHF rises to approximately 200 pg/ml. At this cutpoint the area under the receiver operating characteristic curve is 0.81, indicating that BNP is of diagnostic value in this group. Importantly, the precursor molecule N-terminal proBNP has a stronger correlation with eGFR of approximately −0.60, and is influenced by the age-related decline in renal function above the lower bounds of normal of <60 ml/min/1.73 m2. Because BNP is a principal messenger from the heart to the kidneys, and because it is influenced by renal filtering function, parenchymal mass, and tubular function, BNP can be leveraged in assisting in the diagnosis and management of combined heart and renal failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McCullough PA, Philbin EF, Spertus JA, et al. Confirmation of a Heart Failure Epidemic: Findings from the Resource Utilization Among Congestive Heart Failure (R.E.A.C.H.) Study. J Am Coll Cardiol 2002;39:60–69.

    Google Scholar 

  2. Graves EJ:Washington DC.U.S. Department of Health and Human Services, Detailed diagnoses and procedures, national hospital discharge survey, 1990. National Center for Health Statistics, Vital and Health Statistics, 1991. (Series 13, No. 113, DHHS Publ. No. (PHS) 92–1774).

  3. Hoes AW, Mosterd A, Grobbee DE. An epidemic of heart failure? Recent evidence from Europe. Eur Heart J 1998;19(Suppl L):L2–L9.

    Google Scholar 

  4. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J AmColl Cardiol 1993;22(4 Suppl A):6A–13A.

    Google Scholar 

  5. Zannad F, Braincon S, Juilliere Y, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: The EPICAL Study. Epidemiologie de l'Insuffisance Cardiaque Avancee en Lorraine. J Am Coll Cardiol 1999;33:734–742.

    Google Scholar 

  6. Meyer KB, Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: Report from the National Kidney Foundation Task Force on cardiovascular disease. J Am Soc Nephrol 1998;9(12 Suppl):S31–S42.

    Google Scholar 

  7. Collins AJ. End-stage renal disease. Are we ready for an emerging epidemic? Postgrad Med 2000;108(1):13–15.

    Google Scholar 

  8. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–470.

    Google Scholar 

  9. Nagagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy. Evidence for BNP as an “emergency” cardiac hormone against ventricular overload. J Clin Invest 1995;96:1280–1287.

    Google Scholar 

  10. Maeda K, Takayoshi T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825–832.

    Google Scholar 

  11. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002;39:131–138.

    Google Scholar 

  12. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681–689.

    Google Scholar 

  13. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41(1):47–55.

    Google Scholar 

  14. Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The cardiovascular health study. J Am Coll Cardiol 2001;37(4):1042–1048.

    Google Scholar 

  15. McCullough PA, Duc P, Omland T, McCord J, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study.Am J Kidney Dis 2003;41(3):571–579.

    Google Scholar 

  16. ProBrain Natriuretic Peptide Package Insert. Roche Diagnostics Incorporated, Indianapolis, IN, 2002.

  17. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97(19):1921–1929.

    Google Scholar 

  18. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102(2):203–210.

    Google Scholar 

  19. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509–516.

    Google Scholar 

  20. Sudoh T, Maekawa K, Kojima M, et al. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem Biophys Res Commun 1989;159:1427–1434.

    Google Scholar 

  21. Kojima M, Minamino N, Kangawa K, et al. Cloning and sequence analysis of cDNA encoding a precursor for rat brain natriuretic peptide. Biochem Biophys Res Commun 1989;159:1420–1426.

    Google Scholar 

  22. Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274(5 Pt 2):H1684–H1689.

    Google Scholar 

  23. Pedersen EB, Pedersen HB, Jensen KT. Pulsatile secretion of atrial natriuretic peptide and brain natriuretic peptide in healthy humans. Clin Sci (Lond) 1999;97:201–206.

    Google Scholar 

  24. Stein BC, Levin RI. Natriuretic peptides: Physiology therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998;135:914–923.

    Google Scholar 

  25. Parmley WW. Pathophysiology of congestive heart failure. Am J Cardiol 1985;56:7A–11A.

    Google Scholar 

  26. Wegner M, Ganten D, Stasch JP. Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats. Hypertens Res 1996;19:229–238.

    Google Scholar 

  27. Ozaki J, Shimizu H, Hashimoto Y, et al. Enzymatic inactivation of major circulating forms of atrial and brain natriuretic peptides. Eur J Pharmacol 1999;370:307–312.

    Google Scholar 

  28. Totsune K, Takahashi K, Satoh F, et al. Urinary immunoreactive brain natriuretic peptide in patients with renal disease. Regul Pept 1996;63:141–147.

    Google Scholar 

  29. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981–2997.

    Google Scholar 

  30. Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic peptide concentrations in patients with endstage renal disease: Role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001;76:1111–1119.

    Google Scholar 

  31. Akiba T, Tachibana K, Togashi K, et al. Plasma human brain natriuretic peptide in chronic renal failure. Clin Nephrol 1995;44(Suppl 1):S61–S64.

    Google Scholar 

  32. National Kidney Foundation. Clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kid Disease 2002;2(Suppl 1):S46–S75. ]

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. William Beaumont Hospital, Royal Oak, MI

    Peter A. McCullough & Keisha R. Sandberg

Authors
  1. Peter A. McCullough
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keisha R. Sandberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter A. McCullough.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCullough, P.A., Sandberg, K.R. B-Type Natriuretic Peptide and Renal Disease. Heart Fail Rev 8, 355–358 (2003). https://doi.org/10.1023/A:1026195332025

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026195332025

Search

Navigation